Genelux (GNLX) FCF Margin (2022 - 2024)

Genelux (GNLX) recorded quarterly FCF Margin of 54800.0% in Q1 2024, down 1882.55% quarter-over-quarter from 2764.12% in Q1 2023, and down 5203588.0% on a YoY basis from N/an in Q2 2023.

Genelux (GNLX) FCF Margin (2022 - 2024) Analysis & Trends

Genelux's FCF Margin history runs 3 years deep, the most recent figure standing at 54800.0% for Q1 2024.

  • In Q1 2024, FCF Margin fell 5203588.0% year-over-year to 54800.0%; the TTM figure through Dec 2024 stood at 270112.5% (down 25758309.0% YoY), while the FY2025 annual figure was 329975.0%, down 5986250.0% from the prior year.
  • FCF Margin was 54800.0% for Q1 2024 at Genelux, down from 2764.12% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 14.02% in Q4 2022 to a low of 54800.0% in Q1 2024.
  • Historically, FCF Margin has averaged 19183.37% across 3 years, with a median of 2764.12% in 2023.
  • Biggest YoY gain for FCF Margin was 5203588 bps in 2024; the steepest drop was 5203588 bps in 2024.
  • A 3-year view of FCF Margin shows it stood at 14.02% in 2022, then slumped by 19820 bps to 2764.12% in 2023, then plunged by 1883 bps to 54800.0% in 2024.
  • The last three FCF Margin figures came in at 54800.0% (Q1 2024), 2764.12% (Q1 2023), and 14.02% (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -3.98%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 43.35%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Genelux 129.36 Mn 129.36 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2024 -54,800.00%
Mar 31, 2023 -2,764.12%
Dec 31, 2022 14.02%